Abstract
A microbial and enzymatic process for xylitol production that initiates from D-glucose occurs by virtue of a three-step process in which D-arabitol is the first intermediate product and D-xylulose is the second. To date, the steps of the formation of D-arabitol and the conversion of xylitol from D-xylulose are key points of departure for promoting the overall process for xylitol production from D-glucose. This review provides comprehensive insights regarding potential methods of xylitol production from D-glucose, which might be an alternative to the classical process that utilizes D-xylose as substrate.
Keywords: D-arabitol dehydrogenase (ArDH), D-arabitol, D-glucose, D-xylulose, xylitol dehydrogenase (XDH), xylitol.
Graphical Abstract
Current Organic Chemistry
Title:Microbial and Enzymatic Process for Xylitol Production from D-glucose
Volume: 18 Issue: 24
Author(s): Xianghui Qi, Xu Wang, Jing Lin, Jingfei Zhu, Yan Luo, Wenying Deng, Fei Wang, Wenjing Sun and Jianzong Meng
Affiliation:
Keywords: D-arabitol dehydrogenase (ArDH), D-arabitol, D-glucose, D-xylulose, xylitol dehydrogenase (XDH), xylitol.
Abstract: A microbial and enzymatic process for xylitol production that initiates from D-glucose occurs by virtue of a three-step process in which D-arabitol is the first intermediate product and D-xylulose is the second. To date, the steps of the formation of D-arabitol and the conversion of xylitol from D-xylulose are key points of departure for promoting the overall process for xylitol production from D-glucose. This review provides comprehensive insights regarding potential methods of xylitol production from D-glucose, which might be an alternative to the classical process that utilizes D-xylose as substrate.
Export Options
About this article
Cite this article as:
Qi Xianghui, Wang Xu, Lin Jing, Zhu Jingfei, Luo Yan, Deng Wenying, Wang Fei, Sun Wenjing and Meng Jianzong, Microbial and Enzymatic Process for Xylitol Production from D-glucose, Current Organic Chemistry 2014; 18 (24) . https://dx.doi.org/10.2174/138527281824150119095755
DOI https://dx.doi.org/10.2174/138527281824150119095755 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women
Endocrine, Metabolic & Immune Disorders - Drug Targets CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Dietary Compounds, Epigenetic Modifications and Metabolic Diseases
Current Chemical Biology Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation
Current Pharmaceutical Design Polycystic Ovary Syndrome and Infertility: From Molecular Perspective
Current Women`s Health Reviews Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus
Current Diabetes Reviews Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies New Insights about Regulatory T Cells Distribution and Function with Exercise: The Role of Immunometabolism
Current Pharmaceutical Design Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients
Current Drug Metabolism Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology